Review Article

You have full text access to this OnlineOpen article

Landmark trials in endocrine adjuvant therapy for breast carcinoma

  1. William Gradishar M.D.†,‡,*

Article first published online: 24 JAN 2006

DOI: 10.1002/cncr.21707

Issue

Cancer

Cancer

Volume 106, Issue 5, pages 975–981, 1 March 2006

Additional Information

How to Cite

Gradishar, W. (2006), Landmark trials in endocrine adjuvant therapy for breast carcinoma. Cancer, 106: 975–981. doi: 10.1002/cncr.21707

Author Information

  1. Feinberg School of Medicine, Northwestern University, Chicago, Illinois

  1. †

    Fax: (312) 695-6189

  2. ‡

    Dr. Gradishar has served as a consultant to AstraZeneca, Novartis, and Pfizer.

*Feinberg School of Medicine, Northwestern University, 676 North St. Clair St., Suite 850, Chicago, IL 60611

  1. †

    Fax: (312) 695-6189

  2. ‡

    Dr. Gradishar has served as a consultant to AstraZeneca, Novartis, and Pfizer.

Publication History

  1. Issue published online: 17 FEB 2006
  2. Article first published online: 24 JAN 2006
  3. Manuscript Accepted: 15 NOV 2005
  4. Manuscript Revised: 6 SEP 2005
  5. Manuscript Received: 29 JUL 2005

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (78K)

Keywords:

  • breast carcinoma;
  • endocrine adjuvant therapy;
  • tamoxifen;
  • aromatase inhibitors;
  • clinical trials

Abstract

The review summarizes the outcomes of several landmark trials involving aromatase inhibitors that helped formulate current therapeutic approaches recommended by the American Society of Clinical Oncology for breast carcinoma treatment. Cancer 2006. © 2006 American Cancer Society.

View Full Article (HTML) Get PDF (78K)